Teva Can't Fight FDA's New Generic-Exclusivity Policy: Judge
Teva Pharmaceuticals' closely watched challenge to the U.S. Food and Drug Administration's new policy on generic-drug exclusivity is premature because the company may have forfeited exclusivity under other policies, a D.C....To view the full article, register now.
Already a subscriber? Click here to view full article